Iptacopan
VIDEO: Patients face many challenges after glomerular disease diagnosis
In these videos, Koyal Jain, MD, MPH, FASN, associate professor of medicine and director, nephrology and hypertension training program at UNC School of Medicin, discusses the latest advancements in glomerular diseases.
Study: Iptacopan superior to placebo in reducing proteinuria at 9 months
LONG BEACH, Calif. — Iptacopan may be superior to placebo in reducing proteinuria at 9 months, with early onset and effect consistency, according to data presented at the National Kidney Foundation Spring Clinical Meetings, here.
FDA approves Fabhalta for treatment of paroxysmal nocturnal hemoglobinuria
The FDA approved iptacopan for treatment of adults with paroxysmal nocturnal hemoglobinuria.
VIDEO: Glomerular diseases treatment space 'booming'
In these videos, Koyal Jain, MD, MPH, FASN, associate professor of medicine and director, nephrology and hypertension training program at UNC School of Medicin, discusses the latest advancements in glomerular diseases.
VIDEO: Better education, mentorship needed for patients with glomerular diseases
In these videos, Koyal Jain, MD, MPH, FASN, associate professor of medicine and director, nephrology and hypertension training program at UNC School of Medicin, discusses the latest advancements in glomerular diseases.
VIDEO: Personalization key aspect of glomerular disease treatment
In these videos, Koyal Jain, MD, MPH, FASN, associate professor of medicine and director, nephrology and hypertension training program at UNC School of Medicin, discusses the latest advancements in glomerular diseases.
VIDEO: Positioning complement inhibitors for treatment of glomerular diseases
In these videos, Koyal Jain, MD, MPH, FASN, associate professor of medicine and director, nephrology and hypertension training program at UNC School of Medicin, discusses the latest advancements in glomerular diseases.
Iptacopan may become preferred treatment for hemolytic paroxysmal nocturnal hemoglobinuria
NEW ORLEANS — Patients with paroxysmal nocturnal hemoglobinuria who received iptacopan vs. standard therapy had clinically meaningful and significant improvement in symptoms, results of the phase 3 APPLY-PNH trial showed.
Iptacopan exhibits preliminary success for treatment of IgA nephropathy
VIDEO: New targets under investigation 'act on different targets across the chain of IgA nephropathy'
In this video, Ali Poyan Mehr, MD, Regional Director of the Glomerular Disease Program at Kaiser Permanente Northern Califorina, provides insight into several ongoing studies into future IgA nephropathy treatments.